1.0 2026-04-04 18:11:41 UTC 2026-08-21 17:48:08 UTC Enzalutamide SmallMolecule Enzalutamide is an organic compound with the formula C21H16F4N4O2S1 and an average molecular weight of 464.44 g/mol. Enzalutamide belongs to the imidazolidines, a subclass of azolidines within the organic compounds. It is categorized as an organoheterocyclic compound. The substance acts as an inhibitor of the androgen receptor (AR). Enzalutamide is used as a treatment for prostate cancer (PMC10313599, PMC7728060, PMC8855934). It has been released from two recorded sources: electric hearing aids (Electrical & Electronic Equipment) and hormone antagonists and related agents (Healthcare, pharmaceuticals & veterinary products). The recorded exposure route for this compound is oral. Associated health effects include hypertension (PMC9869701), fatigue (PMC9869701), and cognitive impairment (PMC9869701). 10.1021/jm301714s 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-me 4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-4-keto-5,5-dimethyl-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylidene-1-imidazolidinyl]-2-fluoro-N-methylbenzamide 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylidene-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-fluoro-N-methylbenzamide 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl-benzamide 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-imidazolidin-1-yl]-2-fluoro-N-methyl-benzamide 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-N-methylbenzamide 4-{3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl}-2-fluoro-N-methylbenzamide 4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluoro-N-methylbenzamide 93T0T9GKNU Benzamide, 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methyl- BR-72825 Enzalutamida Enzalutamide Enzalutamide (MDV3100) Enzalutamide(MDV3100) Enzalutamide, MDV3100, MDV-3100, MDV 3100 Enzalutamidum MDV 3100 MDV 3100?(Enzalutamide)/4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide MDV-3100 MDV-3100|MDV3100|Xtandi® MDV3100 MDV3100 (Enzalutamide) MDV3100 Enzalutamide n-methyl-4-[3-(4-cyano-3-trifluoromethylphenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl]-2-fluorobenzamide UNII-93T0T9GKNU UNII:93T0T9GKNU Xtandi Xtandi® [915087-33-1] C21H16F4N4O2S1 464.437 464.093009 915087-33-1 CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC(=C(C=C1)C#N)C(F)(F)F InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30) WXCXUHSOUPDCQV-UHFFFAOYSA-N Detected and Not Quantified Enzalutamide Drug Metabolism SMP0130793 Enzalutamide Drug Metabolism Action Pathway SMP0144209 logp 4.16 average_mass 464.437 ChemAxon mono_mass 464.093009 ChemAxon smiles CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=CC(=C(C=C1)C#N)C(F)(F)F ChemAxon formula C21H16F4N4O2S1 ChemAxon inchi InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30) ChemAxon inchikey WXCXUHSOUPDCQV-UHFFFAOYSA-N ChemAxon #<HealthEffect::ActiveRecord_Associations_CollectionProxy:0x00007f722665cee0> DB08899 15951529 13093347 BE0000132